The objective is to formulate clinical practice guidelines for treating Cushing's syndrome.
Containing relevant Learning Zones, guidelines, trials and news.
Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
Classical pituitary apoplexy is a medical emergency and rapid replacement with hydrocortisone maybe life saving. It is caused by haemorrhage and/or infarction of a tumour within the pituitary gland.
Melatonin 1mg/ml oral solution is indicated for the short-term treatment of jet-lag in adults.
Recodati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people with endogenous Cushing’s syndrome, the company announced. The decision follows a European Medicines Agency (EMA) committee recommendation in November to approve Isturisa for that purpose.
Recodati's inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people...
Corcept Therapeutics Incorporated announced that GRACE, the Phase III trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), met its primary endpoint
The purpose of the guidelines is to encourage the widespread adoption of harmonized good practice in the diagnosis and management of patients with pituitary apoplexy.
Xeris Biopharma announced the FDA approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.